Introduction: Elderly patients account for the majority of lung cancer diagnoses but are poorly represented in clinical trials. We evaluated the overall survival (OS) of elderly patients with stage III NSCLC treated with definitive radiation compared with that of patients treated with definitive chemoradiation.
Introduction
Stage III NSCLC represents 30% of all new lung cancer diagnoses and is a heterogeneous disease requiring a multidisciplinary treatment approach. 1 Nearly 70% of all lung cancer diagnoses and more than 70% of lung cancer deaths in the United States occur in patients 65 years of age or older. 2 However, elderly individuals are underrepresented in clinical trials, making treatment decisions in this population challenging.
Overall, the available data guiding decision making in elderly individuals are limited. A multicenter retrospective review based on the Netherlands Cancer Registry reported no improvement in overall survival (OS) for patients age 70 years or older who were treated with concurrent chemoradiation (CCRT) compared with that of patients treated with sequential chemoradiation (SCRT) or radiation therapy (RT) alone. 6 In contrast, two additional studies, including a subset analysis of two prospective trials and a Surveillance, Epidemiology, and End Results-Medicare analysis, demonstrated a survival benefit for chemoradiation (CRT). 7, 8 Given the conflicting and scant data on this patient population, the optimal treatment strategy for stage III NSCLC in elderly individuals needs to be further defined.
The objective of this study was to compare OS in elderly patients treated with RT alone with OS in elderly patients treated with CRT by using the National Cancer Database (NCDB). We hypothesized that patients who received CRT would have improved OS compared with those treated with RT alone.
Materials and Methods
The NCDB, which is a combined effort of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society, is a nationwide hospital-based database that contains deidentified hospital registry data from more than 1500 accredited facilities, representing more than 70% of newly diagnosed cancer cases in the United States. 9 The NCDB collects data on patient demographics and comorbidities, tumor characteristics and staging details, primary therapies administered, and OS. The CoC's NCDB and the hospitals participating in the CoC NCDB are the source of the de-identified data, and they have not verified and are not responsible for either the statistical validity of the data analysis or the conclusions presented in this study.
Patient Selection
Patients in whom stage III NSCLC was diagnosed from 2003 to 2014 were collected from the NCDB participant user file, with additional inclusion and exclusion criteria summarized in Figure 1 . We defined elderly patients as those age 70 years or older, as previously defined in numerous studies. [10] [11] [12] The transition to the seventh edition of the American Joint Committee on Cancer (AJCC) staging system occurred in 2010; consequently, our patient cohort consisted of patients staged by using both the sixth and seventh editions of the AJCC staging system. Patients with clinical T4N0M0 disease based on the AJCC sixth edition were excluded, as they could be either clinical stage II (T3 N0 M0) or stage IV (M1a [malignant pleural or pericardial effusion]) based on the AJCC seventh edition. Because the focus of this study was on patients not treated surgically, those treated with any type of surgical procedure were excluded. Additional exclusion criteria included unknown RT or chemotherapy details, treatment with regional or total RT doses of 80 Gy or higher, treatment with more than 45 fractions of RT, treatment with immunotherapy, no treatment, treatment with chemotherapy alone, and treatment with palliative doses of RT (<59.4 Gy). After exclusion, patients were categorized as having received definitive RT alone (59.4 Gy) or definitive CRT (59.4 Gy). Patients in the CRT group were considered to have received CCRT if chemotherapy was delivered within 30 days before or after initiation of RT, whereas SCRT was defined as RT delivered more than 30 days after initiation of chemotherapy, as defined in a prior study. 13 Details regarding radiation treatment technique (e.g., three-dimensional conformal RT versus intensity-modulated RT) were available for 35% of the patient population. Rather than exclude patients with an unknown treatment technique, we chose not to include this variable in our analysis. Patients with unknown demographic data were excluded. For the urban or rural code, the 2013 classification codes were used, whereas income was determined by using the 2008-2012 code. Finally, patients with less than 1 month of follow-up were excluded from the analysis to limit immortal time bias. 14 
Study Variables
We dichotomized the following baseline covariates: sex (male versus female), race (white versus nonwhite), median income ($48,000 versus <$48,000), primary insurance payer (private versus nonprivate), county location (metropolitan versus urban or rural), facility type (academic versus community versus comprehensive community versus integrated network programs), chemotherapy agents used (multiagent regimen versus single-agent regimen), and clinical stage group (IIIB versus IIIA). The Charlson-Deyo score, a measure of comorbidity, was dichotomized as 0 (no comorbities) or 1 (1 comorbidity). The variables age and distance to the nearest facility were analyzed as continuous variables.
Statistical Methods
The primary objective of this study was to evaluate OS in elderly patients treated with CRT versus with RT alone. We also sought to evaluate the impact of number of chemotherapy agents used (multiagent CRT versus RT alone, single-agent CRT versus RT, and multiagent CRT versus single-agent CRT). Additional analysis included comparison of OS in patients in the CRT group treated with CCRT versus with SCRT. Differences in patient characteristics between patients treated with CRT and those treated with RT were tested by using the c 2 test for categorical variables and the t test for continuous variables. Survival was estimated by using the KaplanMeier method, and the log-rank test was used to compare survival curves. Cox regression analysis was used to test the association between treatment and demographic variables with OS on univariate analysis. Variables with a p value of 0.10 or less on univariate analysis were included in the multivariate model.
Propensity score matching (PSM) was performed to reduce potential selection bias. Logistic regression was used to identify predictors of treatment with definitive CRT versus definitive RT alone. Patients treated with CRT were matched with those receiving radiation alone by a 1:1 nearest available neighbor match without replacement by using an algorithm described by CocaPerraillon. 15 The caliper size was calculated as 20% of the SD of the propensity score as described by Rosenbaum et al. 16 Common support of the propensity score distributions was evaluated graphically, and balance was evaluated by computing the standardized difference of the covariates across the two groups. 17 After PSM, OS was estimated by the Kaplan-Meier method and Cox regression was used to perform univariate and multivariate analysis. The exact same approach was used to perform PSM for patients receiving CCRT versus SCRT. All statistical analyses were performed with SAS, version 9.4 (SAS Institute, Inc., Cary, NC).
Results

Patient Characteristics
We identified 5023 elderly patients treated with RT alone and 18,206 patients treated with CRT. The median radiation dose was 64.8 Gy (interquartile range [IQR] 61.2-66.6 Gy) over a median of 34 fractions (range 33-36) in the CRT group and 64.8 Gy (IQR 60.0-66.6 Gy) over a median of 33 (range 30-35) in the RT group. The radiation was delivered with conventional fraction sizes with a median daily fraction size of 1.8 Gy (range 1.8-2.0 Gy) in the CRT group and 2.0 Gy (range 1.8-2.0 Gy) in the RT group. Several imbalances in characteristics existed between patients in the RT group and those in the CRT group (Table 1 
Predictors of Receiving CRT versus RT
We identified both clinical and demographic variables associated with elderly patients receiving definitive CRT treatment (Supplementary Table 1 ). On univariate analysis, younger age, male sex, white race, higher income, living in a nonmetropolitan county, stage IIIB disease, increased distance from the treating hospital, and a Charlson-Deyo score less than 1 were associated with higher odds of receiving CRT. All of these covariates, except for living in a metropolitan county, were independently associated with higher odds of receiving CRT on multivariate logistic regression analysis and were used to calculate propensity scores. After PSM, the propensity score distributions between the two groups showed nearly ideal common support ( Supplementary  Fig. 1A ). The covariates were well balanced between the two treatment groups after PSM with standardized differences between the covariates well below 10% (Supplementary Table 2 ).
Predictors of Receiving CCRT versus SCRT
Supplementary Table 3 demonstrates that among patients in the CRT group, factors associated with receipt of CCRT compared with SCRT included male sex, treatment at a nonacademic treatment facility, stage IIIA disease, and higher comorbidity index. All of these factors remained significant on multivariate logistic regression analysis and were used to calculate propensity scores. Supplementary Figure 1B and Supplementary Table 4 demonstrate that PSM resulted in well-balanced groups.
Survival Outcomes in the CRT Cohort versus in the RT Cohort
At the time of analysis, 19,041 of the 23,229 patients had died. The median follow-up for all elderly patients was 15.5 months (IQR 8.3-28.8 months) and the median follow-up for survivors was 30.7 months (IQR 19.1-49.8 months). We used Cox univariate and multivariate analyses to identify patient and treatment factors associated with OS (Supplementary Table 5 ). Factors independently associated with improved OS included younger age, female sex, nonwhite race, treatment at an academic facility, higher income, living in a metropolitan county, stage IIIA versus stage IIIB disease, closer distance to the treatment hospital, Charlson-Deyo score less than 1, longer time to start of RT, and CRT versus RT alone.
Before PSM, the median OS was 18.1 months (95% confidence interval [CI]: 17.8-18.5 months) for patients treated with CRT and 12.2 months (95% CI: 11.7-12.6 months) for patients treated with RT (p < 0.001) (Fig. 2A) . With PSM, a CRT therapy match was successfully identified for 4718 of the 5023 patients treated with RT (caliper size of 0.03 based on a propensity score SD of 0.13). In the matched cohort, the survival advantage of CRT over RT alone persisted, with median OS times of 17.2 months (95% CI: 16.6-17.8) and 12.2 months (95% CI: 11.8-12.6), respectively (p < 0.001) (Fig. 2B) .
On univariate analysis in the matched cohort of elderly patients receiving CRT versus RT, factors associated with worse OS included older age, male sex, white race, nonacademic treatment facility, nonmetropolitan location, stage IIIB disease, Charlson-Deyo score higher than 0, and treatment with RT alone (Supplementary Table 6 ). After adjustment for confounders, CRT corresponded to a 33% reduction in the risk for death (hazard ratio [HR] ¼ 0.67, 95% CI: 0.64-0.70, p < 0.001) ( Table 2 ). The benefit of CRT was greater for elderly patients treated with multiagent chemotherapy (HR ¼ 0.64, 95% CI: 0.61-0.67, p < 0.001) (Fig. 3B and Table 2 ) than for those treated with single-agent chemotherapy (HR ¼ 0.83, 95% CI: 0.75-0.92, p < 0.001) (Fig. 3A and Table 2 ). As demonstrated in Figure 3C and Table 2 , for elderly patients treated with CRT, multiagent chemotherapy resulted in a 21% decrease in the HR for death compared with that for 
Survival Outcomes in Patients Treated with CCRT versus with SCRT
Elderly patients treated with definitive CRT were further subdivided into those treated with CCRT and those treated with SCRT on the basis of timing of initiation of radiation and chemotherapy. Of the 18,203 patients treated with definitive CRT, 15,840 received CCRT and 2366 received SCRT. The median OS was significantly higher in patients treated with SCRT than in those treated with CCRT: 20.0 months (95% CI: 19.1-20.9) versus 17.8 months (95% CI: 17.4-18.2) (p < 0.001) (Fig. 4A) . PSM identified a CCRT match for all 2366 patients treated with SCRT (caliper size of 0.004 based on a propensity score SD of 0.02). Supplementary Table 6 demonstrates the univariate OS analysis in the matched CCRT versus SCRT cohorts. On multivariate analysis, SCRT corresponded to a 9% reduction in the risk for death (HR ¼ 0.91, 95% CI: 0.85-0.96, p ¼ 0.002) ( Table 2 and Fig. 4B ). We performed a sensitivity analysis in which the definition of CCRT was restricted to patients who received chemotherapy within 14 days of the initiation of RT, and the survival benefit of SCRT over CCRT persisted. CRT, chemoradiation; RT, radiation therapy; CCRT, concurrent chemoradiation; SCRT, sequential chemotherapy and radiation; HR, hazard ratio; CI, confidence interval; NS, p value > 0.10 on univariate analysis; N/A, not applicable.
Discussion
Treatment of elderly individuals with locally advanced NSCLC is challenging, and with an aging population, it will remain an issue for the U.S. health care system for the foreseeable future. 18 To our knowledge, our study represents the largest reported cohort of elderly patients with stage III NSCLC not treated surgically. We found that combined modality therapy with radiation and chemotherapy results in improved OS compared with radiation alone in elderly patients and that sequential therapy appears superior to concurrent therapy.
We found a significant OS benefit with the addition of chemotherapy to definitive RT, with a 33% reduction in risk of death. Prior studies evaluating combined modality therapy in elderly patients have reported conflicting results. For example, a retrospective study using the Netherlands Cancer Registry also evaluated elderly (70 years old) patients with unresectable stage III NSCLC and reported no survival benefit with CCRT and increased toxicity. 6 In contrast, a second analysis of patients aged 65 years or older compared CCRT with RT alone and demonstrated a survival benefit (13.7 versus 10.5 months [p ¼ .05]) for CRT compared with for RT alone. 8 However, the rates of grade 3 or higher toxicity were significantly higher in the CRT group (89.9%) versus in the RT-alone group (32.4%). Similarly, Davidoff et al. found that CRT had a significant survival benefit when compared to RT alone (12.0 versus 7.6 months) in patients 66 years of age and older. 7 In general, limited prospective data of CRT versus RT alone in elderly patients with stage III NSCLC exist. Two trials from Japan have evaluated CRT versus RT in elderly patients, the first of which was stopped early on account of four deaths in the CRT arm. 19 In a subsequent phase III trial that completed accrual, Atagi et al. found that CRT improved OS compared to RT alone in 197 patients older than 70 years (HR ¼ 0.68). 10 The chemotherapy in this trial included single-agent lowdose carboplatin (30 mg/m 2 for 20 days). There were higher rates of grade 3 or 4 hematologic toxicity and grade 3 infection in the CRT group, although rates of grade 3 or 4 radiation pneumonitis and late lung toxicity were similar between the groups. In a recent metaanalysis of the 243 patients treated on both Japanese trials and an additional 164 elderly patients from the 2006 analysis of CRT using platinum compounds that was reported by Auperin et al., the use of CRT was associated with a 34% reduction in the HR for death, which is similar to the 33% reduction seen in our study that included over 9,000 patients in the matched cohort. 20 Additionally, we found a modest but significant 15% reduction in the risk for death when nonstandard single-agent chemotherapy is used.
In this NCDB analysis, we found that survival in elderly patients treated with SCRT had a 9% reduction in risk for death compared with CCRT. This finding is in contrast to the results of the 2010 meta-analysis by Auperin et al., which demonstrated an OS benefit with CCRT versus with SCRT for patients with locally advanced NSCLC. 21 Elderly individuals were underrepresented in that analysis, with only 15% of patients age 70 years or older. Our results were similar to those from the Surveillance, Epidemiology, and End Results-Medicare database study reported by Davidoff et al., which that found an increased mortality risk with CCRT compared with that with SCRT. 7 However, this finding from our analysis must be taken with caution. Because the NCDB does not collect duration of chemotherapy treatment, it is not possible to determine whether patients in the SCRT group received combined modality therapy at the time of radiation.
The toxicity of combined modality therapy is a central issue in the management of elderly patients. 12, [22] [23] [24] Several studies have found significantly higher rates of toxicity in patients receiving CRT versus RT alone. 6, 8, 10, 19, 25 In a recent pooled analysis of patients with stage III NSCLC treated with CRT in one of 16 U.S. National Cancer Institute cooperative group studies, the 832 elderly patients (70 years old) experienced more toxicity, a higher rate of treatment-related death, and worse OS compared with the 2768 nonelderly patients. 12 Given the strict eligibility criteria and close follow-up required in clinical trials, the rates of adverse events and/or deaths and survival outcomes are likely worse in the nonclinical trial elderly population. Nonetheless, our results demonstrate that elderly patients treated with CRT had survival superior to that of elderly patients treated with RT alone. This underscores the importance of identifying and incorporating tools such as the Comprehensive Geriatric Assessment or Vulnerable Elders Survey-13 into the treatment decision-making process. 18, 26, 27 Completion of the Comprehensive Geriatric Assessment can help predict risk for toxicity with treatment, and it can be used to fine-tune treatment recommendations 28 ; its use has been endorsed by the International Society for Geriatric Oncology and the European Organization for Research and Treatment of Cancer. 27, 29 This study has several limitations. The NCDB is a retrospective database with inherent weaknesses that include incomplete data, selection bias, and unmeasured confounders. One major limitation of the NCDB is that performance status is not captured. Instead, the Charlson-Deyo score, which measures the number of comorbidities that each patient has, is collected. We fully recognize that there is no single variable or group of variables in any data set that can accurately reflect the treatment decision for an individual patient. Therefore, although PSM was utilized to minimize treatment selection bias, imbalances in unmeasured variables between the treatment cohorts likely remain. The NCDB does not collect several key chemotherapy details, including specific agents used and the duration/number of cycles delivered. This makes it impossible to determine whether patients received consolidation chemotherapy. Also, although an OS benefit was observed with definitive CRT versus with definitive RT alone, there are no available data in the NCDB regarding critically important end points of toxicity, quality of life, and cause of death.
Nonetheless, we feel that there are several strengths to be noted. This is by far the largest analysis of CRT versus RT (and CCRT versus SCRT) in elderly patients to date. Although chemotherapy details are limited in the NCDB, the RT data are much more complete. The RT doses captured in the NCDB are those that were delivered, not those intended, and we ensured that patients received definitive doses of RT (59.4 Gy) to be included in this analysis. Although the exact chemotherapy regimen is not reported, the NCDB does collect data on whether one agent or more than one agent was used. We feel that the analysis of survival by number of chemotherapy agents used provides a useful framework for how to approach the elderly patient with stage III NSCLC.
Treatment of elderly patients with stage III NSCLC should involve a multidisciplinary discussion. All patients not eligible for surgery should first be considered for CRT, with either concurrent or sequential radiation. On the basis of our findings, multiagent chemotherapy is preferred over single-agent regimens in suitable patients. When multiagent chemotherapy is not feasible, a single-agent regimen is supported by our results, as well as by those of Atagi et al. 10 When chemotherapy is contraindicated or not recommended, definitive RT alone should be considered.
In conclusion, we found that definitive CRT is superior to definitive RT in elderly patients with stage III NSCLC not treated surgically. We also found that in patients who received CRT, sequential chemotherapy and RT resulted in better OS than in those who received CCRT. Although the optimal methodology for deciding on appropriate therapy in these patients is unknown, future clinical trials in stage III NSCLC should prioritize inclusion of elderly patients to help further tailor therapeutic decisions for this expanding patient population.
